NY-ESO-1 108–116 (HLA-A*02:01) SLAQDAPPL

The peptide NY-ESO-1 127-136 (TVSGNILTIR) is a linear peptidic epitope derived from the human Cancer/Testis Antigen 1 (NY-ESO-1; UniProt: P78358). This decamer is specifically recognized in the context of the HLA-A*68:01 allele, providing a crucial tool for studying immune responses in diverse genetic backgrounds. While many NY-ESO-1 studies focus on the A*02 allele, epitopes like TVSGNILTIR (IEDB ID: 2274788) are essential for a comprehensive understanding of the T-cell landscape across broader patient populations.Looking for a more comprehensive solution? This specific epitope is included in our NY-ESO-1 Sub Peptide Pool and the full NY-ESO-1 Peptide Pool, allowing you to study this sequence as part of a larger antigenic context.Scientific Validation & RelevanceDespite being a more specialized target, this epitope is scientifically documented: MHC Interaction: Validated in MHC ligand assays to confirm its binding affinity to the HLA-A*68:01 molecule.Literature Presence: Investigated in peer-reviewed publications focusing on the expansion of known NY-ESO-1 epitopes beyond the most common HLA types. Key Applications HLA-Specific Immune Monitoring: Ideal for researchers focusing on HLA-A*68:01 positive cohorts in clinical or translational studies. Epitope Discovery & Mapping: A vital component for mapping the full immunogenic potential of the NY-ESO-1 protein. Vaccine & TCR-T Development: Use as a specific control or target sequence for developing immunotherapies tailored to a wider array of HLA backgrounds. Why choose peptides&elephants? At peptides&elephants, we specialize in providing high-purity peptides that meet the rigorous demands of immunological research. Our NY-ESO-1 127-136 epitope is synthesized with uncompromising quality to ensure that your assays—from ELISpot to Flow Cytometry—yield reproducible and reliable data.

SLLMWITQC - The Essential Reference for Precision Immunotherapy SLLMWITQC is not just another epitope—it is one of the most thoroughly characterized HLA-A*02:01 restricted sequences (IEDB epitope ID 59278) in cancer immunology. Derived from both Cancer/testis antigen 1 (NY-ESO-1; UniProt: P78358) and the LAGE-1A isoform of Cancer/testis antigen 2 (UniProt: O75638-2), this peptide offers unique dual-targeting potential. It is the essential specialist tool for anyone developing or validating therapies aimed at these potent human tumor antigens.  Why this Peptide is Your Essential Specialist Tool This peptide is the specific positive control to show if your anti-cancer weapon is functional. Validate Your TCR-T Cells: Use SLLMWITQC to verify that your engineered T-cell receptors correctly recognize and react to their target. Reference Vaccine Success: A critical reference to monitor if your vaccine has successfully primed an antigen-specific immune response. Eliminate Assay Guesswork: As a high-affinity binder, it provides a reliable "on" signal, ensuring that your detection system (ELISpot, ICS, or Multimer staining) is working perfectly. Proven Performance, IEDB-Validated With over 500 validated T-cell assays and 85+ publications, SLLMWITQC is a trusted sequence for: Cytokine Profiling: Reliable induction of IFN-ƴ, TNF-α, and IL-2. Cytotoxicity Assays: The standard trigger for T-cell mediated tumor cell lysis. In Vivo Referencing: Proven efficacy in reducing tumor burden in adoptive transfer models. Your Research, Our Precision At peptides&elephants, we support your NY-ESO-1 research with a modular toolkit of high-quality synthetic peptides. We provide SLLMWITQC as: High-Quality Individual Peptide for precise kinetic and functional studies. Part of a Targeted Sub-Pool with 5 key peptides for broader screening. Part of our Complete Peptide Pool covering the entire 180 AA sequence. Use the Button above to request a quote | Explore the NY-ESO-1 Insights Page

The peptide NY-ESO-1 157-165 mutant 165V with the amino acid sequence SLLMWITQV (IEDB epitope ID 59283) is a modified linear epitope derived from the human Cancer/Testis Antigen 1 (NY-ESO-1; UniProt ID: P78358). This specific variant, often referred to as the 165V analog, features a C-terminal substitution of Cysteine to Valine. This modification is widely used in cancer immunotherapy research to improve the stability of the peptide-MHC complex. As a heteroclitic peptide, SLLMWITQV often demonstrates enhanced binding affinity to HLA-A*02:01 compared to the wild-type sequence, making it a critical tool for expanding and detecting NY-ESO-1 specific CD8+ T-cells.Scientific Significance & ApplicationsThe SLLMWITQV analog is one of the most extensively studied peptides in tumor immunology:Enhanced Immunogenicity: Studied for its ability to elicit stronger T-cell responses than the native sequence, making it a prime candidate for cancer vaccine development and TCR-T cell priming.Comprehensive Validation: Heavily documented in T-cell assays, B-cell assays, and MHC ligand binding studies.Precision Tool: Ideal for the stimulation, identification, and sorting of NY-ESO-1 specific CD8+ T-lymphocytes.Part of an Immunodominant Cluster This peptide is a key component of the highly immunogenic NY-ESO-1 157-170 cluster. This region is recognized by multiple HLA alleles, allowing for comparative immunological studies: NY-ESO-1 157-165 (SLLMWITQC): The native HLA-A*02:01 Wild-Type. NY-ESO-1 158-166 (LLMWITQCF): Optimized for HLA-A*24:02. NY-ESO-1 162-170 (ITQCFLPVF): Targeted for HLA-B*15:17. Why choose peptides&elephants? We provide this analog peptide with the high-quality required for reproducible immunological results. Our synthesis process ensures that the specific 165V modification is precisely maintained, offering you a reliable reference for your potency assays and immune monitoring. Use the Button above to request a quote | Explore the NY-ESO-1 Overview

The peptide NY-ESO-1 158-166 (LLMWITQCF) is a highly immunogenic linear nonamer (IEDB Epitope ID: 1075452) that serves as a vital tool for studying CD8+ T-cell responses in HLA-A*24:02 positive populations.This sequence is particularly unique as it is identical in both NY-ESO-1 (Cancer/Testis Antigen 1; UniProt ID: P78358) and LAGE-1a (Cancer/Testis Antigen 2; UniProt ID: O75638-2). This dual occurrence makes it a high-priority target for cancer immunotherapy, as it allows for the simultaneous targeting and monitoring of multiple tumor-associated antigens.Scientific Significance & Cross-ReactivityLLMWITQCF is one of the most thoroughly validated epitopes for the HLA-A*24:02 allele, which is highly prevalent in Asian and Caucasian cohorts: Dual Antigen Targeting: Because this sequence is shared between NY-ESO-1 and LAGE-1, it is frequently used to develop pan-CTA (Cancer/Testis Antigen) directed therapies. Extensive Validation: Documented in major publications and confirmed by independent T-cell assays and MHC ligand binding studies. Proven Immunogenicity: Validated for its ability to stimulate specific IFN-gamma release and cytotoxic T-lymphocyte (CTL) activity against HLA-A*24 positive tumor cells. Applications T-Cell Monitoring: Tracking antigen-specific immune responses in clinical trials targeting NY-ESO-1 or LAGE-1. TCR-T Development: A gold-standard reference for validating the specificity and potency of HLA-A*24:02 restricted T-cell receptors. Epitope Mapping: Key component of the NY-ESO-1 157-170 cluster, allowing researchers to study overlapping immune responses across different HLA backgrounds. Complete your analysis of the NY-ESO-1 157-170 Region: For the HLA-A*02:01 benchmark, see SLLMWITQC (Wild-Type). For the enhanced stability analog, see SLLMWITQV (165V). For the HLA-B*15:17 epitope, see ITQCFLPVF.  Use the Button above to request a quote | Explore the NY-ESO-1 Overview Why choose peptides&elephants? We provide the NY-ESO-1 158-166 epitope with the precision and quality required for high-stakes immunological research. Our synthesis ensures that this critical nonamer delivers consistent, reproducible results in every assay—from ELISpot to advanced Flow Cytometry profiling. Target two major tumor antigens with one validated HLA-A*24:02 epitope.

The peptide NY-ESO-1 162-170 (ITQCFLPVF) is a linear nonamer derived from the human Cancer/Testis Antigen 1 (NY-ESO-1; UniProt: P78358). This specific sequence is a key tool for researchers investigating T-cell responses restricted to the HLA-B*15:17 allele.As part of the immunodominant cluster spanning residues 157 to 170, this peptide allows for the precise mapping of CD8+ T-cell activity at the C-terminal boundary of this highly reactive region. Scientific Significance While many studies focus on HLA-A*02, the inclusion of B-allele restricted epitopes is essential for a complete understanding of tumor-specific immunity: Epitope Cluster Integration: This peptide overlaps with the "Gold Standard" 157-165 region, providing a critical perspective on how different HLA molecules (A vs. B alleles) compete for or share overlapping sequences. Allele-Specific Research: Optimized for use in cohorts where HLA-B*15:17 is a relevant genetic background, ensuring that no T-cell response remains undetected due to limited HLA-coverage. Structural Studies: Ideal for investigating the binding motifs and stability of the HLA-B*15 family when presenting NY-ESO-1 derived peptides. Applications Advanced Epitope Mapping: Defining the exact C-terminal reach of T-cell recognition within the NY-ESO-1 157-170 hotspot. T-Cell Assay Control: Use as a specific positive control in IFN-$\gamma$ ELISpot or intracellular cytokine staining (ICS) for HLA-B*15:17 positive samples. Multi-Allele Screening: A necessary component for "Pan-HLA" screening panels to ensure comprehensive immune monitoring in clinical trials. Broaden your NY-ESO-1 research with this specialized HLA-B*15:17 restricted epitope.

NY-ESO-1 86–94 (RLLEFYLAM) is a well-characterized linear peptide epitope derived from the human cancer/testis antigen 1 (NY-ESO-1, UniProt: P78358). Restricted to HLA-A*02:01, this nonamer peptide has been extensively studied for its immunogenic potential in cancer immunology. According to the Immune Epitope Database (IEDB epitope ID: 1075626), RLLEFYLAM has at least been: Reported in 6 peer-reviewed publications Tested in 7 T cell assays, demonstrating strong CD8⁺ T cell reactivity Assessed in 1 B cell assay and 2 MHC ligand assays Background on NY-ESO-1 and CTAs NY-ESO-1 is one of the most immunogenic cancer/testis antigens (CTAs). CTAs are normally expressed only in germ cells of the testis but become aberrantly re-expressed in many cancers, including melanoma, lung, ovarian, and esophageal tumors. Because the testis is an immune-privileged site, the immune system does not develop tolerance to these antigens—making them highly attractive targets for cancer immunotherapy and immune monitoring. These characteristics have positioned NY-ESO-1, and epitopes like RLLEFYLAM, at the center of research into cancer vaccines, adoptive T cell therapies, and diagnostic assays. T cell epitope cluster NY-ESO-1 86–94 (RLLEFYLAM) is part of an immunodominant cluster. Depending on your HLA-restriction of interest, you might also consider: NY-ESO-1_LAGE-2 91-101 (YLAMPFATPME) – Optimized for HLA-A*24:02 NY-ESO-1 93-101 (AMPFATPME) – Optimized for HLA-B*07:02 NY-ESO-1 94-102 (MPFATPMEA) – Optimized for HLA-B*35:01 & HLA-B*51:01 peptides&elephants provides NY-ESO-1 86–94 with the highest quality standards, ensuring reliable results in immunological research and translational applications. Use the Button above to request a quote | Explore the NY-ESO-1 Overview

The peptide epitope NY-ESO-1 93–101 (AMPFATPME) is derived from the human cancer/testis antigen 1 (NY-ESO-1) with the UniProt-ID P78358. This nonamer peptide (IEDB epitope ID: 2265540) is restricted to HLA-B*07:02 and has been investigated for its role in antigen-specific T cell responses in cancer immunology. NY-ESO-1 and CTAs NY-ESO-1 belongs to the family of cancer/testis antigens (CTAs), proteins typically restricted to germ cells of the testis but aberrantly expressed in many tumors, including melanoma, lung, ovarian, and esophageal cancers. Because of this unique expression profile and their strong immunogenicity, CTAs like NY-ESO-1 are widely recognized as prime targets for cancer immunotherapy, immune monitoring, and vaccine development. NY-ESO-1 epitopes such as AMPFATPME contribute to dissecting CD8⁺ T cell responses and advancing the development of diagnostic assays and adoptive T cell therapies. T cell epitope cluster  This peptide is part of an immunodominant epitope cluster. Depending on your HLA-restriction of interest, you might also consider: NY-ESO-1 86-94 (RLLEFYLAM) – Optimized for HLA-A*02:01 NY-ESO-1_LAGE-2 91-101 (YLAMPFATPME) – Optimized for HLA-A*24:02 NY-ESO-1 94-102 (MPFATPMEA) – Optimized for HLA-B*35:01 & HLA-B*51:01 peptides&elephants supplies NY-ESO-1 93–101 with uncompromising quality, enabling reliable, reproducible, and translationally relevant results for immunological research. Use the Button above to request a quote | Explore the NY-ESO-1 Overview

NY-ESO-1 94-102 (MPFATPMEA) is a specialized nonamer covering the sequence position 94-102 of the human Cancer/Testis Antigen 1 (NY-ESO-1; UniProt: P78358). This epitope is uniquely recognized by human CD8+ T-cells in the context of both HLA-B*35:01 and HLA-B*51:01 molecules. Key Features: Dual HLA Restriction: Ideal for research involving diverse donor groups with B35 or B51 backgrounds. Single-Cell Analysis: Highly effective for the analysis and sorting of individual antigen-specific T-cells via multimer staining or functional assays. Immunodominant Region: Part of the high-density epitope cluster (aa 86-102), essential for comprehensive epitope mapping. Applications: Identification and characterization of rare antigen-specific T-cell populations. Research into HLA cross-reactivity and MHC-peptide stability. Development of personalized immunotherapy protocols. Explore the NY-ESO-1 86-102 Epitope Cluster Depending on your HLA-restriction of interest, you might also consider: NY-ESO-1 86-94 (RLLEFYLAM) – Optimized for HLA-A*02:01 NY-ESO-1_LAGE-2 91-101 (YLAMPFATPME) – Optimized for HLA-A*24:02 NY-ESO-1 93-101 (AMPFATPME) – Optimized for HLA-B*07:02 Use the Button above to request a quote | Explore the NY-ESO-1 Overview  

Comprehensive Antigen Scan for Complete T-Cell Profiling The NY-ESO-1 Peptide Pool from peptides&elephants is a high-performance tool designed for the thorough analysis of T-cell responses against Cancer/Testis Antigen 1 (NY-ESO-1). Unlike focused sub-pools, this comprehensive pool consists of 43 overlapping peptides (15-mers with an 11-amino acid overlap) spanning the entire length of the NY-ESO-1 protein (UniProt ID: P78358). The peptide scan approach ensures that no potential epitope is missed, making it the ideal tool for screening both CD4+ and CD8+ T-cell responses regardless of the donor's HLA type. The NY-ESO-1 Peptide Pool is optimized for T-cell assays such as ELISpot, ICS and Flow Cytometry. Why Use a Full Antigen Scan? The 15-mer overlapping strategy is the most robust method for immunological profiling: Unbiased Discovery: Identifies all relevant epitopes across the entire protein sequence. Dual Activation: The 15-amino acid length is ideal for presentation on both MHC Class I and Class II molecules, activating both CD8+ and CD4+ T-cells. HLA-Independent: Suitable for use with any donor sample, as it covers all possible HLA-restricted motifs. Applications & Scientific Validation This peptide pool is a staple in clinical cancer research and immune monitoring. Its efficacy in detecting tumor-specific immune responses has been demonstrated in various high-impact studies. Featured Research: Our NY-ESO-1 pool was a key component in studying immune landscapes in gastrointestinal cancers. For a deep dive into the application of this pool in detecting tumor-associated antigens and HLA-I expression, read our detailed article: 👉 Esophagogastric adenocarcinoma: Tumor-associated antigens, immune responses and HLA-I ExpressionMap the full immune response to NY-ESO-1 with our validated NY-ESO-1 Peptide Pool.

The NY-ESO-1 Sub Peptide Pool from peptides&elephants is a specialized collection of 5 highly validated, overlapping peptides derived from the human Cancer/Testis Antigen 1 (NY-ESO-1; UniProt ID: P78358). While full protein scans provide a broad overview, this Sub Pool focuses on key immunodominant regions, including the reference epitope SLLMWITQC. This high quality peptide pool is the ideal tool for precise T-cell monitoring, TCR-validation, and the development of targeted cancer vaccines. Included Peptide Sequences The NY-ESO-1 Sub Peptide Pool covers a diverse range of HLA restrictions, ensuring broad applicability across different donor profiles: SLLMWITQC: NY-ESO-1 157-165 (HLA-A*02:01)SLLMWITQV: NY-ESO-1 157-165 mutant (HLA-A*02:01) 165VLLMWITQCF: NY-ESO-1 158-166 (HLA-A*24:02)TVSGNILTIR: NY-ESO-1 127-136 (HLA-A*68:01)MPFATPMEA: NY-ESO-1 94-102 (HLA-B*35:01) (HLA-B*51:01) Key Applications Antigen-Specific T-Cell Stimulation: Ideal for ELISpot, Intracellular Cytokine Staining (ICS), and flow cytometry assays. TCR-T Cell Validation: A critical positive control for verifying the specificity and potency of engineered T-cell receptors. Immune Monitoring: Reliable benchmarking of patient immune responses in clinical trials and vaccination studies. Epitope Mapping: Focused screening of dominant NY-ESO-1 regions across multiple HLA alleles.

HLA-A*24:02 Restricted Epitope for Cancer Immunotherapy NY-ESO-1_LAGE-2 91-101 (YLAMPFATPME) is a well-characterized linear peptidic epitope (Epitope ID: 1075852) derived from the human Cancer/Testis Antigen 1 (NY-ESO-1; UniProt: P78358). This undecamer is a key target for studying immune reactivity in HLA-A*24:02 positive populations, a frequent allele in Asian and Caucasian cohorts. Scientific Validation: This epitope has been validated in peer-reviewed literature and immunological databases: Immune Reactivity: Studied in multiple publications and confirmed in independent T-cell assays. Functional Response: Proven to trigger IFN-gamma release and specific cytotoxicity. MHC Binding: Documented positive qualitative binding for HLA-A*24:02. Applications: Monitoring of antigen-specific CD8+ T-cell responses. Validation of TCR-T cell therapies and cancer vaccine candidates. Cytotoxicity assays (CTL assays) for oncology research. NY-ESO-1_LAGE-2 91-101 is part of an immunodominant cluster. Depending on your HLA-restriction of interest, you might also consider: NY-ESO-1 86-94 (RLLEFYLAM) – Optimized for HLA-A*02:01 NY-ESO-1 93-101 (AMPFATPME) – Optimized for HLA-B*07:02 NY-ESO-1 94-102 (MPFATPMEA) – Optimized for HLA-B*35:01 & HLA-B*51:01  Use the Button above to request a quote | Explore the NY-ESO-1 Overview